A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1990-06-01
Target enrollment:
Participant gender:
Summary
To study the natural course of AIDS related Kaposi's sarcoma and to determine the usefulness
and safety of weekly administration of small doses of doxorubicin.
Doxorubicin is one of the most active of all antitumor agents but at currently used doses
toxicity is common. When small doses are administered on a weekly schedule, the toxicity of
the drug appears to be reduced.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)